All News
STAT+: Our biggest burning questions on Trump’s order to bring down drug prices
Trump's executive order lacks specifics and raises questions on what can be accomplished, what will be challenged in court.
Read MoreAlzheimer's Brain Edema, Bleeding Rates Reported in Lecanemab Real-World Study
(MedPage Today) -- Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well, a retrospective study at one specialty memory clinic sh
Read MoreFDA/CDC Call Time Out on Ixchiq Vaccine for Older Adults
(MedPage Today) -- Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse eve
Read MoreZepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...
(MedPage Today) -- Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.
Read MoreElizabeth Holmes rises again — or at least her partner does
The emergence of Haemanthus, a company formed by Elizabeth Holmes’ partner, Billy Evans, triggered a mix of shock, anger, and rueful skepticism.
Read MoreAntihypertensives at Bedtime: No Better or Worse Than in the Morning
(MedPage Today) -- Bedtime administration of antihypertensives, while safe, failed to provide additional cardiovascular benefit when put to the test in a randomized trial.
Read MoreBecoming obese under age of 30 ‘raises risk of early death by at least 75%’
Study finds early adulthood weight gain has disproportionate effect on mortality riskBecoming obese under the age of 30 increases the chances of premature death by more than 75%, a large-scale study h
Read MoreLong-Term Human Albumin Fails to Improve Survival in Decompensated Cirrhosis
(MedPage Today) -- Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute decompensation and ascites, the phase III randomized PR
Read MoreSTAT+: OpenAI leaps into health care with AI benchmark to evaluate models
OpenAI on Monday released a large set of data for evaluating how well large language models answer questions related to health care.
Read MoreSTAT+: Trump’s drug-pricing order takes a hard line against pharma. Investors shrugged
President Trump unveiled his plan to dramatically overhaul the way the U.S. pays for drugs. Pharma investors didn't seem to care.
Read More